All In Biotech

Drug Trial Radar · NCT07035405

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 7,500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

7,500

Planned (sponsor's estimate)

Start

Jul 4, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shenzhen Medical Academy of Research and Translation
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.

Conditions

  • Stroke

Interventions

  • Colchicine 0.5 mgDrug

    Oral colchicine will be initiated with a dose of 0.5 mg per day.

  • Placebo colchicineDrug

    Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Event of ischemic stroke, myocardial infarction and vascular deathTime frame: From randomization to occurrence of the first event, with a median follow-up time of 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.